Promoter methylation of Wnt/β-Catenin signal inhibitor TMEM88 is associated with unfavorable prognosis of nonsmall cell lung cancer

作     者：Rongna Ma Nannan Feng Xiao Yu Hongyan Lin Xiaohong Zhang Oumin Shi Huan Zhang Shuo Zhang Lei Li Min Zheng Ming Gao Herbert Yu Biyun Qian 

作者机构：Hongqiao International Institute of MedicineShanghai Tongren Hospital/Faculty of Public HealthShanghai Jiao Tong University School of Medicine Key Laboratory of Cancer Prevention and TherapyTianjin Medical University Cancer Institute and Hospital Cancer Epidemiology ProgramUniversity of Hawaii Cancer Center 

出 版 物：《Cancer Biology & Medicine》 (癌症生物学与医学（英文版）)

年 卷 期：2017年第14卷第4期

页      面：377-386页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：supported by the National Natural Science Foundation of China(Grant No.81573231) the Medical Professionals Crossing Project of Shanghai Jiao Tong University(Grant No.YG2015ZD01) 

主　　题：TMEM88 lung cancer methylation prognosis Wnt/β-Catenin signaling 

摘      要：Objective:Recent research has indicated that altered promoter methylation of oncogenes and tumor suppressor genes is an important mechanism in lung cancer development and *** this study,we investigated the association between promoter methylation of TMEM88,a possible inhibitor of the Wnt/β-Catenin signaling,and the survival of patients with nonsmall cell lung cancer(NSCLC).Methods:Twelve pairs of tumor and adjacent non-tumor samples were used for microarray analyses of DNA methylation and gene *** validation,more than two hundred additional samples were analyzed for methylation using bisulfite pyrosequencing and for gene expression using q *** the cell function were tested by wound healing,transwell,CCK8 and cell cycle ***:Our analysis of patient specimens showed that TMEM88 methylation was higher in NSCLC tumors(82.2%±10.3,P56 months;P=0.021).In addition,we found that demethylation treatment could inhibit tumor cell proliferation,migration,and invasion,which was supportive of an association between methylation and ***:Based on these consistent observations,we concluded that TMEM88 may play an important role in NSCLC progression and that promoter methylation of TMEM88 may serve as a biomarker for NSCLC prognosis and treatment.